Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07282743

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Led by Sun Pharmaceutical Industries Limited · Updated on 2026-03-18

285

Participants Needed

21

Research Sites

79 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.

CONDITIONS

Official Title

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to sign written informed consent
  • Men or women aged 18 years or older at consent
  • Diagnosed with type II diabetes mellitus at least 180 days before screening
  • HbA1c between 7.0% and 10.5% at screening
  • Stable BMI of 27 kg/m2 or higher for at least 90 days before screening
  • Able and willing to fast and perform 7-point self-monitoring blood glucose for 3 days before visits
  • On stable daily metformin dose for at least 90 days before screening
  • Not using other diabetes medications besides metformin for at least 3 months before screening
  • Women of childbearing potential must use highly effective contraception plus barrier method during and 1 month after study
  • Male participants with partners of childbearing potential must use barrier contraception during and 30 days after study
  • Women of childbearing potential must have negative pregnancy tests before treatment
  • Willing and able to follow study protocol and use electronic patient-reported outcome device
Not Eligible

You will not qualify if you...

  • History of type I diabetes mellitus
  • Weight change over 5% within 90 days before screening
  • History of pancreatitis or more than 3 hypoglycemic episodes in 90 days before screening
  • Chronic kidney disease with eGFR below 60
  • Poorly controlled hypertension (systolic >160 mmHg or diastolic >100 mmHg)
  • Poorly controlled thyroid disorders
  • Diabetes or obesity caused by endocrine disorders or medications
  • Previous or planned obesity surgery or weight loss device during trial
  • History of major depressive disorder in past 2 years or severe psychiatric illness
  • Any lifetime history of suicide attempt
  • Certain medical conditions affecting study safety or results as judged by investigator
  • Recent heart attack, unstable angina, or stroke within past 6 months
  • Personal or family history of certain thyroid cancers or heart rhythm problems
  • Planned surgery during trial except minor procedures
  • Active cancer except certain treated skin or other cancers without recurrence for 5 years
  • Diabetic eye diseases or maculopathy confirmed by exam
  • Moderate to severe vascular disease likely needing intervention
  • Known allergy to study drug or ingredients
  • History of alcohol or drug abuse in past 2 years
  • Using medications with narrow therapeutic index or prolong QT interval
  • Use of other diabetes treatments besides metformin within 90 days before screening
  • Previous use of GLP-1 receptor agonists
  • Use of weight loss supplements or medications within 90 days
  • Participation in weight-loss programs within 90 days
  • Elevated calcitonin levels
  • Abnormal lab tests or uncontrolled diseases posing risk
  • Positive urine drug screen for non-prescribed substances
  • Significant ECG abnormalities or high risk of arrhythmias
  • Pregnant or breastfeeding females

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 21 locations

1

Lynn Institute of the Ozarks

Little Rock, Arkansas, United States, 72204

Actively Recruiting

2

Family First Medical Research Center

Hialeah Gardens, Florida, United States, 33175

Actively Recruiting

3

Alliance for Multispecialty Research (AMR Clinical) - Wichita East

Lakeland, Florida, United States, 33803

Actively Recruiting

4

CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis)

Lakeland, Florida, United States, 33803

Actively Recruiting

5

GTL Medical & Research Group

Miami, Florida, United States, 33173

Actively Recruiting

6

Florida Institute for Clinical Research LLC

Orlando, Florida, United States, 32835

Actively Recruiting

7

AMR Clinical, El Dorado

El Dorado, Kansas, United States, 67042

Actively Recruiting

8

AMR Clinical - Newton

Newton, Kansas, United States, 67114

Actively Recruiting

9

Lynn Health Science Institute - Oklahoma City

Oklahoma City, Oklahoma, United States, 73112

Actively Recruiting

10

Endolife Specialty Hospitals Pvt. Ltd.

Guntur, Andhra Pradesh, India, 522001

Actively Recruiting

11

Life Care Hospital and Research Centre

Bangalore, Karnataka, India, 560092

Actively Recruiting

12

Government Medical College

Kozhikode, Kerala, India, 673008

Actively Recruiting

13

Jothydevs Diabetes Research Centre

Trivandrum, Kerala, India, 695032

Actively Recruiting

14

Nirmal Hospital Private Limited

Kolhāpur, Maharashtra, India, 416008

Actively Recruiting

15

Topiwala National Medical College & BYL Nair Hospital

Mumbai, Maharashtra, India, 400008

Actively Recruiting

16

Seth G. S. medical college and KEM hospital

Mumbai, Maharashtra, India, 400012

Actively Recruiting

17

BSES Municipal General Hospital

Mumbai, Maharashtra, India, 400058

Actively Recruiting

18

LMMF's Deenanath Mangeshkar Hospital and Research Center

Pune, Maharashtra, India, 411004

Actively Recruiting

19

Lady Hardinge Medical College and S.S.K. Hospital

New Delhi, National Capital Territory of Delhi, India, 110001

Actively Recruiting

20

All India Institute of Medical Sciences

New Delhi, National Capital Territory of Delhi, India, 110029

Actively Recruiting

21

Madras Diabetes Research Foundation (MDRF)

Chennai, Tamil Nadu, India, 600086

Actively Recruiting

Loading map...

Research Team

H

Head, Regulatory Affairs

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here